Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: <scp>CARTITUDE</scp> ‐1 (phase 2) Japanese cohort-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE ‐1 (phase 2) Japanese cohort

Published:2022-10-07 Issue:12 Volume:113 Page:4267-4276
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Ri Masaki¹^ORCID,Suzuki Kenshi²,Ishida Tadao²^ORCID,Kuroda Junya³^ORCID,Tsukamoto Taku³,Teshima Takanori⁴,Goto Hideki⁴,Jackson Carolyn C.⁵,Sun Huabin⁵,Pacaud Lida⁶,Fujikawa Ei⁷,Yeh Tzu‐Min⁵,Hatayama Tomoyoshi⁷,Aida Kensuke⁷,Sunagawa Yoshihiro⁷,Iida Shinsuke¹

Affiliation:

1. Department of Hematology and Oncology Nagoya City University Hospital Nagoya Japan

2. Department of Hematology Japanese Red Cross Medical Center Tokyo Japan

3. Division of Hematology and Oncology Kyoto Prefectural University of Medicine Kyoto Japan

4. Department of Hematology Hokkaido University Hospital Sapporo Japan

5. Janssen Research & Development, LLC; Bridgewater New Jersey USA

6. Legend Biotech Piscataway New Jersey USA

7. Janssen Pharmaceutical KK Tokyo Japan

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15556

Reference27 articles.

1. Multiple myeloma: Every year a new standard?

2. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma

3. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe

4. Current developments in immunotherapy in the treatment of multiple myeloma

5. Latest developments in cellular therapy for multiple myeloma;Gregory TK;Oncol Hematol Rev,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3;Japanese Journal of Clinical Oncology;2024-05-24

2. An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2024-05-03

3. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs;Pharmacological Research;2024-05

4. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma;Nature Communications;2024-01-08

5. An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously;Cancer Gene Therapy;2023-12-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3